Physician profile

Sumrine Raja

Internal Medicine · Wyandotte, MI

NPI 1346667219

$315.51

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$315.51

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $84.73 2023 Trelegy Ellipta
Lilly USA, LLC $73.98 2023 Mounjaro, Trulicity, Emgality
Abbvie INC. $43.32 2023
Bayer Healthcare Pharmaceuticals INC. $38.06 2023
Merck Sharp & Dohme LLC $30.73 2023 Verquvo, Belsomra, Steglatro
Exact Sciences Corporation $18.99 2023 Cologuard Collection Kit
Astrazeneca Pharmaceuticals LP $12.98 2023 Farxiga
Janssen Pharmaceuticals, INC $12.72 2023 Xarelto

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sumrine Raja

$315.51

in general payments reported 2019-2025

Years
2023
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/1379473/sumrine-raja

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.